Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.

Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

Open access

Abstract

Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering medications have generated some optimism on the possibility to influence the natural history of cardiorenal complications of T2D. This review summarizes work in the area of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-021-01213-w

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Meta-analysis evaluating the efficacy of SGLT-2i (empagliflozin, canagliflozin and dapagliflozin) on MACE according to basal eGFR values in four trials (EMPA-REG, CANVAS, DECLARE and CREDENCE)
Fig. 1 Meta-analysis evaluating the efficacy of SGLT-2i (empagliflozin, canagliflozin and dapagliflozin) on MACE according to basal eGFR values in four trials (EMPA-REG, CANVAS, DECLARE and CREDENCE)CC BY · PubMed Central
Fig. 2 Random effect meta-analysis of nine trials with five SGLT-21 (empagliflozin, canagliflozin, dapagliflozin, eurtugliflozin, sotagliflozin) on hospitalization for heart failure (HF) in patients with or without T2D, and with or without HF at baseline. Overall hazard ratio (HF) is 0.67 (95% Confidence Intervals 0.60–0.74)
Fig. 2 Random effect meta-analysis of nine trials with five SGLT-21 (empagliflozin, canagliflozin, dapagliflozin, eurtugliflozin, sotagliflozin) on hospitalization for heart failure (HF) in patients with or without T2D, and with or without HF at baseline. Overall hazard ratio (HF) is 0.67 (95% Confidence Intervals 0.60–0.74)CC BY · PubMed Central
Fig. 3 Meta-analysis evaluating the efficacy of SGLT-2i on MACE according to the age at entry in three trials (EMPA-REG, CANVAS and DECLARE)
Fig. 3 Meta-analysis evaluating the efficacy of SGLT-2i on MACE according to the age at entry in three trials (EMPA-REG, CANVAS and DECLARE)CC BY · PubMed Central
Fig. 4 Scenario of cardiorenal effects SGLT-2i in patients with T2D participating in CVOTs. MACE, major adverse cardiovascular events; DKD, diabetic kidney disease. : modest benefit (the hazard ratio -HR- for a given endpoint during treatment with a gliflozin is > 0.85 and < 1.0, as compared with placebo). : moderate benefit (HR ≤ 0.85 and > 0.75). : large benefit (HR ≤ 0.75)
Fig. 4 Scenario of cardiorenal effects SGLT-2i in patients with T2D participating in CVOTs. MACE, major adverse cardiovascular events; DKD, diabetic kidney disease. : modest benefit (the hazard ratio -HR- for a given endpoint during treatment with a gliflozin is > 0.85 and < 1.0, as compared with placebo). : moderate benefit (HR ≤ 0.85 and > 0.75). : large benefit (HR ≤ 0.75)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Research works printed but not linked: 1

  1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46. · DOI · Paper page

Cited by

See all 49

Metadata

Authors
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K.
Affiliations
University of Campania "Luigi Vanvitelli" (IT)
Corresponding author
Giugliano, Dario
Venue
Cardiovascular Diabetology
Published
2021-01-11
Volume
20
Issue
1
Pages
17-17
ISSN
1475-2840 (ISSN-L)
OpenAlex
W3119719361
Cited by
48
References
80
Citations by year
2026: 3 · 2025: 7 · 2024: 6 · 2023: 3 · 2022: 14 · 2021: 15
FWCI
1.46
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders
Associazione Salute con Stile
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
SGLT2 inhibitors, type 2 diabetes, cardiorenal complications, major adverse cardiovascular events, heart failure hospitalization, renal outcomes, end-stage renal disease, primary prevention, secondary prevention, age, older adults, glucose-lowering medications
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Glycemic Control, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Heart Failure, Glycated Hemoglobin, Humans, Primary Prevention, Risk Factors, Biomarkers, Treatment Outcome, Risk Assessment, Secondary Prevention, Diabetic Cardiomyopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. https://app.cochat.ai/papers/10.1186/s12933-021-01213-w
The paper
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021). Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-021-01213-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.